Comparative Study of CT Severity Index and Outcome in Hospitalised Vaccinated and Non Vaccinated Patients of Covid 19 Pneumonia

Modi, Sonali D; Shah, Dharita; Mundhra, Krati S; Gandhi, Bhargav; Shah, Rahul; Kagathara, Vikas; Dharaiya, Madhav Kiritbhai; Modi, Dhruv

doi:10.26502/jrci.2809046

Cited by 5 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These observations were corresponding to the results obtained from our study. Minimal clinical severity as depicted by the lower CT-SSs among the vaccinated people as compared to the unvaccinated population was also reported by other studies [23][24][25].…”

Section: Discussionsupporting

confidence: 81%

Breakthrough Infections: Clinical Profile and Outcomes of COVID-19 Vaccinated and Unvaccinated People From a Tertiary Care Hospital

Shahapur¹,

Shahapur²,

Bagali³

et al. 2022

Cureus

View full text Add to dashboard Cite

IntroductionDespite the availability of a vaccine and extensive vaccination, breakthrough infections are commonly noted, which is jeopardizing the vaccine-based protection against COVID-19. The present study aims to evaluate COVID-19 breakthrough infections and to compare the clinical profile and outcomes of the vaccinated and unvaccinated populations. MethodsA retrospective observational study was conducted for two months (March-April 2021), and all cases reported during the study period were included in the study. Socio-demographic details, COVID-19 profiles, clinical outcomes, vaccination statuses, and types of vaccine were collected from the patients. Further, COVID-19-positive samples were screened for lineages using next-generation sequencing (NGS). ResultsOf the total 103 patients included in the study, 79 (76.7%) were symptomatic and 24 (23.3%) were asymptomatic. Only 32% were vaccinated and 68% were unvaccinated. 29.2% were hospitalized due to COVID-19 and all of them were unvaccinated. The mortality among hospitalized patients was extremely high (60%). The time to positivity after complete vaccination was noted to be 37.09±23.74 days. The unvaccinated study participants showed lower Cycle threshold (Ct) values (E Gene/N Gene: 17.38±4.53) as compared to the vaccinated people (E Gene/N Gene: 22±4.25). The Delta (B. 1.1. 629) (76.7%) was the predominant variant among the study population followed by AY.4 (20.4%) and Kappa (2.9%) variants. ConclusionAlthough the vaccination does not restrict/avoid infection, it appears to protect the vaccinated people from severe forms of COVID-19. Also, the higher Ct values among vaccinated people indicate that the viral load among such people may be lower and, therefore, minimizes viral transmission.

show abstract

Section: Discussionsupporting

confidence: 81%

Breakthrough Infections: Clinical Profile and Outcomes of COVID-19 Vaccinated and Unvaccinated People From a Tertiary Care Hospital

Shahapur¹,

Shahapur²,

Bagali³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Lee JE et al [ 21 ] reported positive chest CT examinations with pneumonia in 78% and 41% of non-vaccinated and vaccinated patients respectively, compared to 81% and 55% in this study. Furthermore, this study particularly agrees with Modi SD et al [ 22 ] regarding the low CT severity scores in the vaccinated patients with comorbidities compared to the non-vaccinated patients. It also matches similar general results of Madhu P et al [ 2 ] study.…”

Section: Discussionsupporting

confidence: 92%

“…The scanning parameters for the chest CT examinations were as follows: [ 1 ] The slice thickness: 1–1.25 mm, [ 2 ] The tube rotation: 0.6–0.9 s, [ 3 ] The detector Collimation 1 mm, [ 4 ] 120–130 kVp, and 200 mA, and [ 5 ] FOV = 350 mm × 350 mm. The examinations were performed without intravenous contrast administration.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

"Sinopharm", "Oxford-AstraZeneca", and "Pfizer-BioNTech" COVID-19 vaccinations: testing efficacy using lung CT-volumetry with comparative analysis of variance (ANOVA)

Samir

Altarawy²,

Sweed³

et al. 2023

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background Several clinical studies tested the efficacy of the different COVID-19 vaccinations while very few radiological researches targeted this issue before. Aim of the work To verify the additive role of lung CT-Volumetry in testing the efficacy of three widely distributed COVID-19 vaccinations; namely the "Sinopharm", "Oxford-AstraZeneca", and "Pfizer-BioNTech" vaccinations, with comparative analysis of variance (ANOVA). Results This study was retrospectively conducted on 341 COVID-19 patients during the period between June/2021 and March/2022. Based on the immunization status, they were divided into four groups; group (A) included 156/341 (46%) patients who did not receive any vaccination (control group), group (B) included 92/341 (27%) patients who received "Sinopharm" vaccine, group (C) included 55/341 (16%) patients who received "Oxford-AstraZeneca" vaccine, group (D) included 38/341 (11%) patients who received "Pfizer-BioNTech" vaccine. Every group was subdivided based on the medical history into three groups; group (1) patients without comorbidities, group (2) patients with comorbidities, and group (3) immunocompromised patients. Automated CT volumetry was calculated for the pathological lung parenchyma. Five CT-severity scores were provided (score 0 = 0%, score 1 = 1–25%, score 2 = 25–50%, score 3 = 51–75%, and score 4 = 76–100%). Analysis of variance (ANOVA) including Tukey HSD testing was utilized in comparison to the non-immunized patients. The "Phizer-Biontech" vaccine succeeded to eliminate severity in patients without and with comorbidity, and also decreased severity in immunocompromised patients (from 79 to 17%). The "Oxford-AstraZeneca" vaccine and to a lesser extent "Sinopharm" vaccine also decreased the clinical severity in patients with comorbidities and immunocompromised patients (from 15 to 9% & 10% as well as from 79 to 20% & 50% respectively). Significant variance was proved regarding the use of "Sinopharm", "Oxford-AstraZeneca", and "Phizer-Biontech" vaccines in patients without comorbidities (f-ratio averaged 4.0282, 10.8049, and 8.4404 respectively, also p-value averaged 0.04632, 0.001268, and 0.004294). Significant variance was proved regarding the use of "Oxford-AstraZeneca", and "Phizer-Biontech" vaccines in patients with comorbidities and immunocompromised patients (f-ratio averaged 4.7521, and 4.1682 as well as 11.7811, and 15.6 respectively, also p-value averaged 0.03492, and 0.04857, as well as both 0.003177, and 0.0009394 respectively, all < 0.05). No significant variance was proved regarding the use of the "Sinopharm" vaccine. Conclusions In addition to the decline of clinical severity rates & CT severity scores, a significant variance was proved regarding the use of the "Sinopharm", "Oxford-AstraZeneca", and "Phizer-Biontech" vaccines in patients without comorbidities. Significant variance was also proved regarding the use of the "Oxford-AstraZeneca" and "Phizer-Biontech" vaccines in patients with comorbidities and immunocompromised patients. Despite that, no significant variance could be proved regarding the use of the "Sinopharm" vaccine in these patients, it decreases the percentage of clinical severity and CT severity scores.

show abstract

“…They found that the vaccinated patients have better outcomes in terms of survival than non-vaccinated patients. 21 In a study done by Kachewar et al showed that post vaccination COVID positives were more frequent in younger population then the elderly patients after vaccination. 22 Vishwanath et al concluded that HRCT is helpful in quantification of lung involvement and the assessment of disease severity in COVID-19.…”

Section: Hrct Thorax Imaging Analysismentioning

confidence: 97%

Comparison of HRCT chest findings among vaccinated and non-vaccinated COVID-19 patients

et al. 2022

View full text Add to dashboard Cite

Background: Coronavirus disease 19 was first reported in Wuhan, China and it was declared a pandemic by WHO in March 12, 2020. Vaccination has provided a very effective way to prevent the spread and reduce the severity of this disease. The two vaccines currently approved by the Government of India are Covaxin and Covishield. HRCT is the most valuable tool available to assess the pulmonary involvement in this disease. The aim of the study was to assess the effect of vaccination on the severity of pulmonary involvement in COVID-19. Methods: A cross-sectional study was conducted in a department of radio diagnosis of tertiary health care hospital of Bihar for period of 4 months from April 2021 to July 2021.Results: The study involved a total of 100 patients (74 were males and 26 females), where 50 were (50%) were unvaccinated and 50 (28.6%) were vaccinated with one or both doses Covishield vaccine. The frequency of disease was least in 14 (7.9%) among fully vaccinated subjects. The CT severity score is less in those who took both doses of the vaccine. The mean CT score of all the patients included in the study was 12.64±11.1. However, the patients who received complete vaccination had significantly low mean CT scores (14.18±7.223) in comparison to the non-vaccinated patients (11.1±6.016). Fully vaccinated patients had almost low CT severity score indicating mild form of disease.Conclusions: HRCT is the most sensitive modality to detect severity of COVID-19 pneumonia. Severe lung involvement is more common in the unvaccinated population (32%) as compared with the vaccinated group, in which only 25% members had severe lung involvement.

show abstract

Comparative Study of CT Severity Index and Outcome in Hospitalised Vaccinated and Non Vaccinated Patients of Covid 19 Pneumonia

Cited by 5 publications

References 0 publications

Breakthrough Infections: Clinical Profile and Outcomes of COVID-19 Vaccinated and Unvaccinated People From a Tertiary Care Hospital

Breakthrough Infections: Clinical Profile and Outcomes of COVID-19 Vaccinated and Unvaccinated People From a Tertiary Care Hospital

"Sinopharm", "Oxford-AstraZeneca", and "Pfizer-BioNTech" COVID-19 vaccinations: testing efficacy using lung CT-volumetry with comparative analysis of variance (ANOVA)

Comparison of HRCT chest findings among vaccinated and non-vaccinated COVID-19 patients

Contact Info

Product

Resources

About